Simple Summary Hepatocellular Carcinoma (HCC) is one of the most common
malignancies in the world with increasing prevalence. This review addresses the current …

The treatment landscape for advanced hepatocellular carcinoma has changed dramatically
over the past 4 years. We now have numerous options for patients in frontline, second-line …

Clinical trials are currently ongoing to evaluate the utility of antibodies against programmed
cell death 1 (PD-1), programmed cell death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte …

Background Immunotherapy with immune checkpoint inhibitors combined with an anti-
angiogenic tyrosine-kinase inhibitor (TKI) has been shown to improve overall survival versus …

Most patients with hepatocellular carcinoma (HCC) are diagnosed at an advanced stage of
disease. Until recently, systemic treatment options that showed survival benefits in HCC …

Abstract Treatment of patients with hepatocellular carcinoma (HCC) in the advanced stage
remains a great challenge, with very few drugs approved. After decades of failure of immune …

Immune checkpoint inhibitors (ICIs) with nivolumab and pembrolizumab are promising
agents for advanced hepatocellular carcinoma (HCC) but lack of effective biomarkers. We …

Hepatocellular carcinoma (HCC) arises on the background of chronic liver disease. Despite
the development of effective anti-viral therapeutics HCC is continuing to rise, in part driven …

Hepatocellular carcinoma (HCC) is one of the world's deadliest and fastest-growing tumors,
with a poor prognosis. HCC develops in the context of chronic liver disease. Curative …

With mortality rates of liver cancer doubling in the last 20 years, this disease is on the rise
and has become the fifth most common cancer in men and the seventh most common …